Keywords: chimerix, gets, 36m, nih, grant, develop, smallpox
Chimerix gets $36M NIH grant to develop smallpox therapy
Article | 15 September 2003
Chimerix Inc, an emerging US biotechnology company developing orally-available, targeted medicines from bioactive molecules, has been awarded a four and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
